|Dr. John A. Scarlett M.D.||Chief Exec. Officer, Pres and Director||1.07M||N/A||66|
|Ms. Olivia Kyusuk Bloom||Chief Financial Officer, Exec. VP of Fin. and Treasurer||595.25k||N/A||48|
|Dr. Andrew J. Grethlein Ph.D.||Exec. VP of Devel. and Technical Operations||627.25k||N/A||53|
|Mr. Stephen N. Rosenfield J.D.||Exec. VP, Gen. Counsel and Corp. Sec.||498.3k||N/A||67|
|Mrs. Melissa A. Kelly Behrs||Exec. VP of Bus. Devel. and Portfolio & Alliance Management||587.48k||N/A||53|
Geron Corporation operates as a biopharmaceutical company. The company supports the clinical stage development of a telomerase inhibitor, imetelstat, for treating hematologic myeloid malignancies. It has collaboration and license agreement with Janssen Biotech, Inc. to develop and commercialize imetelstat worldwide for indications in oncology, including hematologic myeloid malignancies and other human therapeutic uses. The company was founded in 1990 and is based in Menlo Park, California.
Geron Corporation’s ISS Governance QualityScore as of February 1, 2018 is 4. The pillar scores are Audit: 1; Board: 1; Shareholder Rights: 8; Compensation: 6.